

Date: 30/05/2024

To

Department of Corporate Services,
BSE Limited,
Floor 25, P J Tower,
Dalal Street, Mumbai - 400001.

Scrip Code: 526445

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to our intimation letter dated May 23, 2024 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on May 30, 2024, the Directors have interalia, approved the following:

- Approved the audited Standalone and Consolidated Financial Results along with the Audit Report for the quarter & Year ended March 31, 2024 (Q4) pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We, herewith, have attached the copy of the audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2024 along with the Audit Report for the said period.

The Board Meeting commenced at 04.45 p.m. and concluded at 11.55 p.m. The necessary arrangements are in place to publish the audited Standalone and Consolidated financial results in the newspapers. The said financial results will also be available on company's www.indrayani.com and also on BSE website www.bseindia.com.

Kindly take a note of the same.

Thanking You,
Yours Faithfully,

For Indrayani Biotech Limited Limited

SWAMIN Digitally signed by
SWAMINATHAN
ATHAN Date: 2024.05.30
23:55:43 +05'30'

Swaminathan
Whole-time director
DIN: 02481041

Encl: As above



Independent Auditor's Report On Standalone Quarterly Financial Results And Year To Date Results Of The Company Pursuant To The Regulation 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

**To the Board of Directors of
Indrayani Biotech Limited
Chennai**

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of **Indrayani Biotech Limited** (the company) for the quarter ended **31st March 2024** and the year to date results for the period from **1st April 2023** to **31st March 2024** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income(Loss) and other financial information for the quarter ended **31st March 2024** (date of the quarter end) as well as the year to date results for the period from **1st April 2023** to **31st March 2024**.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143 (10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and the accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.



VENKATESH & CO
Chartered Accountants

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Venkatesh & Co
Chartered Accountants
FR No: 04636S



CA Desikan G
Partner
M. No 219101

Date: 30/05/2024
Place: Chennai
UDIN: 24219101BKAPKU9397



VENKATESH & CO

Chartered Accountants

Independent Auditor's Report on consolidated audited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Indrayani Biotech Limited
Chennai**

Report on the audit of the Consolidated Financial Statements

We have audited the accompanying Statement of Consolidated Financial Results of **Indrayani Biotech Limited** (Holding company) and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), its associates and jointly controlled entities for the quarter ended **31st March 2024** and for the period from **01st April 2023 to 31st March 2024** (the Statement), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **31st March 2024** and the corresponding period from **01st April 2023 to 31st March 2024** as reported in these financial results have been approved by the holding company's Board of Directors, but have not been subjected to audit/review.

Management's Responsibilities for the Consolidated Financial Results

These quarterly financial results as well as the year to date consolidated financial results have been prepared on the basis of the interim financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.



VENKATESH & CO

Chartered Accountants

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit



evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

- a) The consolidated Financial Results include the audited Financial Results of **6** Subsidiaries whose Financial Statements reflect Group's share of total assets of **Rs 8,773.85 Lakhs** as at **31st March 2024**, Group's share of total revenue of **Rs 11,626.66 Lakhs** and Group's share of total net profit/(Loss) after tax including other comprehensive Income of **Rs 887.39 Lakhs** respectively for the period from **01st April 2023 to 31st March 2024** as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on interim financial statements/Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- b) Further in addition to the subsidiaries mentioned in point (a) above, we did not audit the statements of **1** subsidiary and **3** step subsidiaries, whose financial statements reflect total assets of **Rs 4,925.39 Lakhs** as at **March 31, 2024**, total revenues of **Rs. 1,543.37**



VENKATESH & CO
Chartered Accountants

Lakhs, total comprehensive income of **Rs 8.63 Lakhs** for the year ended on that date, as considered in the Statement. These financial statements have not audited and been certified by the management. Our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based on the management certified financial statements.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, associates and jointly controlled entities, the Statement:

a. includes the results of the following entities:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	Kniss Laboratories Private Limited	Step Down Subsidiary
6	IBL Thiruvannamalai LLP	Step Down Subsidiary
7	Dindigul Farm Products Limited	Subsidiary (42.59%) **
8	Matrix Boilers Private Limited	Subsidiary
9	IBL Investments Limited	Subsidiary
10	IBL Social Foundation	Subsidiary

is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and

****Consolidation comprises of Financial results of Dindigul Farm Product Limited by virtue of Control established over Board of Directors and decisions of management.**



VENKATESH & CO
Chartered Accountants

- b. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of **Rs. 873.57 Lakhs** of net profit and other comprehensive income(loss)) and other financial information of the Group for the quarter ended **31st March 2024** and for the period from **01st April 2023 to 31st March 2024**.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

For Venkatesh & Co
Chartered Accountants
FRN 004636S



CA. Desikan G
Partner
M.No :219101

Place: Chennai
Date: 30/05/2024
UDIN: 24219101BKAPKV8585

INDRAYANI BIOTECH LIMITED CIN: L40100TN1992PLC129301 Regd. Office : BLOCK 1, MODULE NO.33, 3rd FLOOR, BIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032						
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2024						
SN	PARTICULARS	CONSOLIDATED				
		Quarter Ended			Year Ended	Year Ended
		31-Mar-24 Audited	31-Dec-23 Unaudited	31-03-2023 Audited	31-Mar-24 Audited	31-03-2023 Audited
		Rs. in Lakhs				
1	Income from Operations					
	(a) Net Sales/Revenue from Operations	4,438.02	3,909.27	4,924.75	16,622.56	16,292.79
	(b) Other Income	103.33	8.24	205.00	121.49	448.66
	Total Income from Operations	4,541.35	3,917.52	5,129.75	16,744.06	16,741.45
2	Expenses					
	(a) Cost of Materials consumed	2,609.73	2,444.49	3,184.09	10,321.76	10,221.44
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(608.51)	-	-	(608.51)	-
	(c) Employee benefits expenses	846.13	497.31	730.04	2,392.94	2,354.03
	(d) Finance Costs	551.30	140.71	222.52	988.25	555.68
	(e) Depreciation and amortisation expense	95.96	103.43	115.18	380.06	334.71
	(f) Other expenses	573.45	623.35	693.29	2,172.11	1,994.99
	Total Expenses	4,068.06	3,809.28	4,945.12	16,646.62	16,466.86
3	Total profit / (Loss) before exceptional items and tax	473.29	108.23	184.63	1,097.44	1,280.59
4	Exceptional Items					
	Add: Share of Profit In Associates	-	-	-	-	-
	Less: Written off CWIP	-	-	-	-	(50.00)
5	Total profit / (Loss) before tax	473.29	108.23	184.63	1,097.44	1,230.59
6	Tax Expenses					
	Current Tax	-	-	20.07	61.85	20.07
	Deferred Tax	-	-	20.14	(6.66)	17.45
	Total Tax Expenses	-	-	40.21	55.19	37.52
7	Net Profit / Loss for the period from continuing operations	473.29	108.23	144.42	1,042.25	1,193.07
8	Profit (loss) from discontinued operations before tax					-
9	Tax expense of discontinued operations					-
10	Net profit (loss) from discontinued operation after tax					-
11	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-
12	Total profit (loss) for period	473.29	108.23	144.42	1,042.25	1,193.07
13	Other comprehensive income net of taxes	-	-	-	-	-
14	Total Comprehensive Income for the period attributable to	473.29	108.23	144.42	1,042.25	1,193.07
	Comprehensive income for the period attributable to owners of parent	386.90	98.05	108.08	638.49	873.68
	Total comprehensive income for the period attributable to Non-controlling Interests	86.40	10.19	36.34	405.79	319.39
15	Paid-up equity share capital (Face value Rs.10 each)	4,553.63	4,563.63	3,422.72	4,553.63	3,422.72
16	Earnings per share					
	Basic earnings (loss) per share *(not annualised)	0.58*	0.22*	0.32*	1.40	2.55
	Diluted earnings (loss) per share *(not annualised)	0.58*	0.22*	0.29*	1.40	2.05
Notes:						
1.The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 30th May 2024 and have been subjected to audit by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and Companies (Indian Accounting Standards) Amendment Rules 2018.						
2.The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).						
3.Figures for three months ended 31 March 2024 as reported in these financials results are the balancing figures between unaudited figures, in respect of the half year and the published year to date figures upto the third quarter of the current financial year.						
4. There is an increase in paid-up share capital on account of allotment of 1,13,09,064 equity shares of Face value Rs.10/- each for the quarter & year ended 31 Mar 2024, pursuant to the conversion of 92,50,000 compulsorily convertible preference shares and 20,59,064 convertible warrants as approved at the Board meeting of the Company held on 1st November 2023						
5.The financial results of subsidiaries - Vaasan Medical Centre India Private Ltd and Peekay Mediequip Limited, - are not consolidated in the current statements due to ongoing NCLT procedures. Additionally, the previous year's financial statements for those entities are pending finalization. The Company is closely monitoring developments and will incorporate the subsidiary results in the upcoming quarters once NCLT procedures conclude and financial statements are filed with respective authorities.						
6. Previous period figures have been regrouped wherever necessary.						
7. There is no investor complaint received during the quarter.						
Date : 30/05/2024 Place : Chennai						

For INDRAYANI BIOTECH LIMITED


G. SWAMINATHAN
Director

M/s. INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

Consolidated Balance sheet as at 31/03/2024

	Note	As at 31 Mar 2024	As at 31 Mar 2023
ASSETS			
Non-current assets			
Property, plant and equipment	3	3,907.87	3,411.49
Capital Work in Progress	4	2,029.84	1,374.14
Goodwill	3	2,334.73	2,334.73
Other Intangible Assets	3	-	1.52
Financial assets			
(i) Investments	5	22.33	22.33
(ii) Other financial assets	6	467.93	512.95
Deffered Tax Assets		135.55	3.75
Non-current tax assets	7-A	106.68	162.42
Other Non Current Assets	8-A	-	20.67
Total non-current assets		9,004.93	7,844.00
Current assets			
Inventories	9	4,235.06	1,221.39
Financial assets			
(i) Trade receivables	10	3,952.89	2,997.16
(ii) Cash and cash equivalents	11	58.21	303.67
(iii) Loans	11-A	684.78	236.59
(iv) Other Financial Assets	11-B	2,966.97	965.76
Current Tax Assets (Net)	7-B	136.05	110.40
Other current assets	8-B	2,463.65	1,917.28
Total current assets		14,497.61	7,752.25
TOTAL ASSETS		23,502.54	15,596.25
EQUITY AND LIABILITIES			
Equity			
Equity share capital	12	4,553.63	4,347.72
Other equity	12	2,167.56	1,160.99
Non Controlling Interests	13	905.39	(673.44)
Total equity		7,626.58	4,835.27
Non-current liabilities			
Financial liabilities			
(i) Borrowings	14	6,659.64	2937.03
(ii) Lease Liabilities	15	406.70	631.60
Deffered Tax liabilities	16	102.38	1.38
Total non-current liabilities		7,168.72	3,570.01
Current liabilities			
Financial liabilities			
(i) Borrowings	17	4,106.70	3,337.48
(ii) Lease Liabilities	15	79.34	112.48
(iii) Trade payables		-	3.70
Total outstanding dues to micro enterprises and small enterprises; and Total outstanding dues of creditors other than micro enterprises and small enterprises	19	3,739.04	2,270.13
(iv) Other Financial Liabilities	20	16.87	308.18
Other current liabilities	21	276.88	766.70
Provision	18	488.40	392.30
Total current liabilities		8,707.23	7,190.97
TOTAL EQUITY AND LIABILITIES		23,502.54	15,596.25

For INDRAYANI BIOTECH LIMITED


A. SWAMINATHAN
Director

M/s. INDRAYANI BIOTECH LIMITED
BLOCK I, MODULE NO.33, 3rd FLOOR, BIRCO ELECTRONIC COMPLEX, THIRUVIKA INDUSTRIAL ESTATE, GUINDY, CHENNAI,
600031

CIN : L40100TN1992PLC139301

Consolidated Statement of Cash Flow for the year ended 31st March 2014

Rs. in Lakh

Particulars	As on 31-Mar-14	As on 31-Mar-13
Cash Flows From Operating Activities:-		
Net Profit after Taxation	1,042.27	1,193.09
Adjustment for Non cash items		
Add: Impairment of Fixed Assets	-	50.00
Add: Depreciation	380.53	334.71
Less: Interest Income Notional (As per Ind AS 109)	(4.56)	(3.32)
Add: Notional Rent as per IND AS	-	-
Add: Interest Expenses Notional as per Applicable IndAS	30.12	55.76
Less: Share of profit of Associates		
Other Comprehensive Income	(0.49)	
Adjustment for Non Operating activities		
Add: Interest Paid	958.13	499.92
Less: Interest income	-	-
Cash Flow Before Working Capital changes:-	2,406.00	2,130.16
Decrease (Increase) in Inventories	(3,013.66)	(1,068.16)
Decrease (Increase) in Trade receivables	(955.73)	(1,587.30)
Decrease (Increase) in current assets	(25.65)	(60.73)
Decrease (Increase) in Other Financial Assets	(2,001.21)	(965.76)
Decrease (Increase) in other current assets	(546.38)	(1,842.38)
(Decrease) Increase in Short term borrowings	769.22	2,227.21
(Decrease) Increase in Financial Liabilities	(291.31)	75.37
(Decrease) Increase in Trade payables	1,465.21	1,691.83
(Decrease) Increase in Other Current liabilities	(489.82)	774.24
(Decrease) Increase in Loans	(448.19)	
(Decrease) Increase in Provisions	96.10	244.28
Cash Flow Before Tax and Extraordinary Items:-		
Income Taxes Paid	-	-
Net Cash Flow From Operating Activities	(3,035.42)	1,618.76
Cash Flow from Investing Activities:-		
Less: Purchase of Capital Assets	(1,630.15)	(2,152.75)
Less: Increase / Decrease in Advances for Capital Expenditure	(18.58)	
Add: Goodwill on Consolidation	-	(1,952.11)
Less: Purchase of Investments	0.00	(22.28)
Less: Sale of Capital Assets	6.62	(236.59)
Add: Interest Income	-	
Decrease (Increase) in Loans and advances & Other assets	8.21	(375.62)
Net Cash flow used in Investing Activities	(1,633.90)	(4,739.35)
Cash Flow from Financing Activities:-		
Increase in Borrowings	3,722.61	2,238.52
Increase in Lease Liabilities	-	-
Interest Income Notional (As per Ind AS 109)	4.56	3.32
Increase in Share Capital	463.29	2,328.18
Repayment of Lease Liabilities	(84.83)	(46.33)
Increase in Non Controlling interest	1,578.83	(714.08)
Issue Expenses Paid	(272.36)	
Interest expense	(988.25)	(555.68)
Decrease in borrowings	-	-
Net Cash Flow From Financing Activities	4,423.86	3,273.93
Net Increase/(Decrease) in Cash and Cash Equivalents:-		
(Opening Balance)	303.67	150.33
Net Cash Flow during the year	(245.46)	153.34
(Closing Balance)	58.21	303.67

For INDRAYANI BIOTECH LIMITED


SWAMINATHAN
 Director

INDRAYANI BIOTECH LIMITED
CIN: L40100TN1992PLC129301

Regd. Office :
BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY
CHENNAI - 600032

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st Mar 2024

SN	PARTICULARS	STANDALONE				
		Quarter Ended			Year Ended	Year Ended
		31-03-2024	31-Dec-23	31-03-2023	31-Mar-24	31-03-2023
		Audited	Unaudited	Audited	Audited	Audited
1	Income from Operations					
	(a) Net Sales/Revenue from Operations	1,579.93	1,369.22	2,130.48	6,232.34	7,448.04
	(b) Other Income	344.58	8.17	15.29	361.88	64.19
	Total Income from Operations	1,924.51	1,377.39	2,145.77	6,594.22	7,512.23
2	Expenses					
	(a) Cost of Materials consumed	762.38	772.02	1,243.08	3,515.38	4,149.05
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(c) Employee benefits expenses	490.45	326.53	471.18	1,569.08	1,749.91
	(d) Finance Costs	247.25	77.97	124.30	482.76	278.39
	(e) Depreciation and amortisation expense	35.46	36.71	48.29	144.76	93.28
	(f) Other expenses	226.57	137.79	171.69	581.31	683.70
	Total Expenses	1,762.11	1,351.02	2,058.54	6,293.31	6,954.31
3	Total profit / (Loss) before exceptional items and tax	162.40	26.37	87.23	300.91	557.92
4	Exceptional Items					
	Add: Share of Profit In Associates		-	-	-	-
	Less: Written of CWIP		-	-	-	-
5	Total profit / (Loss) before tax	162.40	26.37	87.23	300.91	507.92
6	Tax Expenses					
	Current Tax	54.17			54.17	2.25
	Deferred Tax	101.00	-	-	101.00	-
	Total Tax Expenses	155.17	-	-	155.17	2.25
7	Net Profit Loss for the period from continuing operations	7.23	26.37	87.23	145.74	505.67
8	Profit (loss) from discontinued operations before tax					
9	Tax expense of discontinued operations					
10	Net profit (loss) from discontinued operation after tax					
11	Share of profit (loss) of associates and joint ventures accounted for using equity method					
12	Total profit (loss) for period	7.23	26.37	87.23	145.74	505.67
13	Paid-up equity share capital (Face value Rs.10 each)	4,553.63	4,553.63	3,422.72	4,553.63	3,422.72
14	Earnings per share					
	Basic earnings (loss) per share *(not annualised)	0.08*	0.06*	0.25*	0.32	1.48
	Diluted earnings (loss) per share *(not annualised)	0.08*	0.06*	0.24*	0.32	1.20

Notes:

1. The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30th May 2024 and have been subjected to audit by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).

3. Figures for three months ended 31 March 2024 as reported in these financials results are the balancing figures between unaudited figures, in respect of the half year and the published year to date figures upto the third quarter of

4. There is no investor complaint received during the quarter.

Date : 30/05/2024

Place : Chennai

For INDRAYANI BIOTECH LIMITED


T. SWAMINATHAN
Director

M/s. INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,
GUINDY, CHENNAI, 600032

Standalone Balance sheet as on 31st Mar 2024

	Note	As at 31 Mar 2024	Rs in Lakh As at 31 Mar 2023
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	3	1,782.42	1,996.97
Capital Work in Progress	4	1,802.91	1,271.96
Goodwill	3	383.53	383.53
Financial assets			
(i) Investments	5	955.81	798.62
(ii) Other financial assets	6	419.52	483.12
Non-current tax assets	7-A	106.17	162.42
Other Non Current Assets		-	-
Total non-current assets		5,450.36	5,096.62
CURRENT ASSETS			
Inventories	9	192.32	186.45
Financial assets			
(i) Trade receivables	10	1,759.63	1,622.70
(ii) Cash and cash equivalents	11	26.29	61.90
(iii) Loans	8-C	3,921.59	1,863.47
(iv) Other Financial Assets	8-A	339.90	401.36
Current Tax Assets (Net)	7-B	136.05	110.40
Other current assets	8-B	774.69	686.85
Total current assets		7,150.47	4,933.13
TOTAL ASSETS		12,600.83	10,029.75
EQUITY AND LIABILITIES			
EQUITY			
Equity share capital	12A	4,553.63	4,347.72
Other equity	12B	897.90	767.13
Total equity		5,451.53	5,114.85
NON-CURRENT LIABILITIES			
Financial liabilities			
(i) Borrowings	13	1487.95	976.01
(ii) Lease Liabilities	14A	406.7	631.6
Deffered Tax liabilities		102.38	1.38
Total non-current liabilities		1,997.03	1,608.99
CURRENT LIABILITIES			
Financial liabilities			
(i) Borrowings	15	4,371.83	2,551.20
(ii) Lease Liabilities	14B	79.34	112.48
(ii) Trade payables		-	-
Total outstanding dues to micro enterprises and small enterprises		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	17	272.34	156.44
(ii) Other Financial Liabilities	18A	-	228.35
Other current liabilities	18B	138.36	71.04
Provision	16	290.38	186.40
Total current liabilities		5,152.25	3,305.91
TOTAL EQUITY AND LIABILITIES		12,600.83	10,029.75

For INDRAYANI BIOTECH LIMITED


G. SWAMINATHAN
Director

M/s. INDRAYANI BIOTECH LIMITED
CIN : L40100TN1992PLC129301
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY,
CHENNAI, 600032

Standalone Cash Flow Statement for the year ended 31/03/2024

Particulars	Amount in Rs. In Lakhs	
	As on 31-Mar-24	As on 31-Mar-23
Cash Flows From Operating Activities:-		
Net Profit after Taxation	300.93	505.68
Adjustment for Non cash items		
Add : Impairment/ Write off of Property Plant and Equipment and Capital Work in Progress	-	50.00
Add : Depreciation	144.76	93.26
Less : Interest Income Notional (As per Ind AS 109)	(4.18)	(3.32)
Add : Notional Rent as per IND AS	-	-
Add: Interest Expenses Notional as per applicable IndAS	30.12	55.76
Adjustment for Non Operating activities		
Add : Interest Paid (Including Interest on Lease Liabilities)	452.64	222.63
Less : Interest income	-	-
Cash Flow Before Working Capital changes:-	<u>924.27</u>	<u>924.01</u>
Decrease (Increase) in Inventories	(5.87)	(49.90)
Decrease (Increase) in Trade receivables	(136.93)	(335.06)
Decrease (Increase) in Current Tax Assets	(25.65)	(60.73)
Decrease (Increase) in Other Financial Assets	61.46	(244.10)
Decrease (Increase) in other current assets	(87.84)	(395.46)
(Decrease) Increase in Short term borrowings	1,820.63	1,556.37
(Decrease) Increase in Financial liabilities	(228.35)	75.37
(Decrease) Increase in Trade payables	115.90	(488.49)
(Decrease) Increase in Other Current liabilities	67.32	(3.24)
(Decrease) Increase in Provisions	103.98	54.46
Cash Flow Before Tax and Extraordinary Items:-		
Income Taxes Paid	-	-
Net Cash Flow From Operating Activities	<u>2,608.93</u>	<u>833.23</u>
Cash Flow from Investing Activities:-		
Less : Purchase of Capital Assets	(634.37)	(189.82)
Less : Purchase of Investments	(157.19)	(780.09)
Add : Rental Receipts	-	-
Add : Amount of Interest Received	-	-
Less : Sale of Capital Assets	-	-
Decrease (Increase) in Loans and advances & Other assets	65.68	(439.20)
Net Cash flow used in Investing Activities	<u>(725.88)</u>	<u>(1,409.11)</u>
Cash Flow from Financing Activities:-		
Increase in Borrowings	511.94	297.50
Interest Income Notional (As per Ind AS 109)	4.18	-
Increase in Share capital	205.91	2,173.75
Issue of Share Warrant	-	154.43
Interest expense(Including Interest on Lease Liabilities)	(482.76)	(222.63)
Repayment of Lease Liabilities	(84.83)	(46.33)
Loan to Group Companies	(2,058.12)	(1,863.47)
Security Premium Received	257.38	-
Issue Expenses Paid	(272.36)	-
Decrease in borrowings	-	-
Net Cash Flow From Financing Activities	<u>(1,918.66)</u>	<u>493.25</u>
Net Increase/(Decrease) in Cash and Cash Equivalents:-		
(Opening Balance)	61.90	144.53
Net Cash Flow during the year	(35.61)	(82.63)
(Closing Balance)	<u>26.29</u>	<u>61.90</u>

- The cash flow statement has been prepared in accordance with the requirements of Indian Accounting Standard – 7 "Cash Flow Statement" issued by the Institute of Chartered Accountants of India.
- Cash flows have been reported using the indirect method, whereby the net profit is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments, segregating between cash flows.
- Significant cash and cash equivalent balances held by the enterprise are available for use by the company.

For INDRAYANI BIOTECH LIMITED


G. SWAMINATHAN
 Director